Key Highlights

  • Intelligent Bio Solutions shares are up 4.15% in pre-market trading to $3.51, extending Thursday's sharp 21.66% close gain to $3.37.
  • The company announced that its Intelligent Fingerprinting Drug Screening Business has been recertified to the ISO 13485:2016 quality management system standard, effective October 14, 2026 and valid for three years.
  • The recertification aligns with the FDA's newly amended Quality Management System Regulation, which incorporated ISO 13485:2016 by reference as of February 2, 2026.
  • Management said the certification supports the company's active application for FDA clearance of its Intelligent Fingerprinting Drug Screening System for detection of the opiate codeine.

What's Driving the Gain

Intelligent Bio Solutions (NASDAQ:INBS) shares are extending a sharp rally in pre-market trading, building on Thursday's 21.66% close gain. Intelligent Bio Solutions is a New York-based medical technology company delivering rapid, non-invasive testing solutions, with its flagship Intelligent Fingerprinting Drug Screening System analyzing fingerprint sweat to detect recent use of drugs such as opiates, cocaine, methamphetamine, and cannabis in under ten minutes.

Today's continued gains follow the company's announcement that its drug screening business has been recertified to the ISO 13485:2016 quality management system standard, the internationally recognized benchmark for medical device manufacturers. The recertification was issued by the British Standards Institution, is effective October 14, 2026, and will remain valid for three years. The company also completed recertification to ISO 9001:2015, the broader international standard for quality management systems.

Why This Matters for FDA Clearance

The timing is notable because the U.S. FDA's amended Quality Management System Regulation came into effect on February 2, 2026, formally incorporating ISO 13485:2016 by reference. As an FDA-registered Facility in the UK, the company's certification demonstrates alignment with the standard now at the core of the FDA's updated regulation, which management said directly supports its active application for FDA clearance of the Intelligent Fingerprinting Drug Screening System for detection of the opiate codeine. The company's certifications support its continued operations across regulated international markets including the United States, Canada, Europe, and Asia Pacific, where its current customer base includes construction, manufacturing, transport and logistics, mining, and drug treatment organizations.

Conclusion

Intelligent Bio Solutions shares are higher in pre-market trading as the company builds on a sharp prior-session rally with news reinforcing its regulatory compliance position ahead of a pending FDA clearance decision. While the recertification itself is a procedural quality-standard update rather than a clearance or commercial milestone, investors appear to be reading it as incremental progress toward the company's broader U.S. regulatory strategy.